While CRP has been proven to be a useful biomarker for predicting many adverse outcomes in STEMI patients, the CRP level changes over time—CRP velocity (CRPv), may be a more sensitive biomarker for identifying patients’ inflammatory state and risk of developing subsequent heart failure. The gene discussed is CRP; the disease is heart failure.